In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Abbvie Inc (NYSE: ABBV) closed the day trading at $185.58 down -1.33% from the previous closing price of $188.09. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 8.76 million shares were traded.
Ratios:
For a better understanding of ABBV, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 59.10 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.41. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.66. In the meantime, Its Debt-to-Equity ratio is 20.40 whereas as Long-Term Debt/Eq ratio is at 18.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 22, 2025, initiated with a Overweight rating and assigned the stock a target price of $210.
Daiwa Securities Downgraded its Outperform to Neutral on December 05, 2024, while the target price for the stock was maintained at $180.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 31 ’25 when Stewart Jeffrey Ryan sold 58,832 shares for $210.08 per share. The transaction valued at 12,359,504 led to the insider holds 53,234 shares of the business.
Stewart Jeffrey Ryan bought 58,832 shares of ABBV for $12,359,897 on Mar 31 ’25. On Mar 14 ’25, another insider, Reents Scott T, who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 17,644 shares for $212.34 each. As a result, the insider received 3,746,527 and left with 11,577 shares of the company.
Valuation Measures:
As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 78.94, and their Forward P/E ratio for the next fiscal year is 13.26. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.72 while its Price-to-Book (P/B) ratio in mrq is 98.53.
Stock Price History:
Over the past 52 weeks, ABBV has reached a high of $218.66, while it has fallen to a 52-week low of $153.58. The 50-Day Moving Average of the stock is -5.67%, while the 200-Day Moving Average is calculated to be -1.93%.
Shares Statistics:
A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.11% of the company’s shares, while institutions hold 73.66% stake in the company.
